Published in Clin Endocrinol (Oxf) on September 01, 1998
Short Synacthen tests--the need for rationalization. Clin Endocrinol (Oxf) (1998) 1.07
An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. Clin Endocrinol (Oxf) (2013) 0.94
Pitfalls in the diagnosis of central adrenal insufficiency in children. Endocr Dev (2009) 0.84
The 1 μg cosyntropin test in normal individuals: A reappraisal. Indian J Endocrinol Metab (2013) 0.82
Evaluation of the hypothalamic-pituitary-adrenal axis function in childhood and adolescence. Neuroimmunomodulation (2009) 0.82
Cortisol response to operative stress with anesthesia in healthy children. J Clin Endocrinol Metab (2013) 0.81
Adrenal Function in females with low plasma HDL-C due to mutations in ABCA1 and LCAT. PLoS One (2014) 0.78
Determining relevant cortisol concentrations in critically ill patients. Crit Care (2010) 0.76
Predictive factors of adrenal insufficiency in patients admitted to acute medical wards: a case control study. BMC Endocr Disord (2013) 0.76
Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol. Eur J Endocrinol (2015) 0.76
How should we interrogate the hypothalamic-pituitary-adrenal axis in patients with suspected hypopituitarism? BMC Endocr Disord (2016) 0.75
Inverted T waves in patient with Addisonian crisis. J Natl Med Assoc (2005) 0.75
An evidence-base for laboratory endocrinology? Clin Biochem Rev (2008) 0.75
Cortisol Response in Healthy and Diseased Dogs after Stimulation with a Depot Formulation of Synthetic ACTH. J Vet Intern Med (2015) 0.75
Cortisol response in short synacthen tests. Clin Endocrinol (Oxf) (1999) 0.75
Delayed diagnosis of Addison's disease: an approach to management. BMJ Case Rep (2014) 0.75
Value of basal serum cortisol to detect corticosteroid-induced adrenal insufficiency in elite cyclists. Eur J Appl Physiol (2006) 0.75
Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet (2001) 7.92
Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab (2001) 4.47
Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet (2001) 4.14
Long-term thyroxine treatment and bone mineral density. Lancet (1992) 3.67
Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab (2006) 3.49
Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types. J Infect Dis (1975) 3.33
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70
Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) (1991) 2.48
Does central obesity reflect "Cushing's disease of the omentum"? Lancet (1997) 2.34
Seasonal variations in serum 25-hydroxycholecalciferol in healthy people. Lancet (1974) 2.19
Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab (2011) 2.16
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 2.16
Elevated cerebrospinal fluid (CSF) leptin in idiopathic intracranial hypertension (IIH): evidence for hypothalamic leptin resistance? Clin Endocrinol (Oxf) (2008) 2.15
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 2.08
Thyroxine replacement therapy and circulating lipid concentrations. Clin Endocrinol (Oxf) (1993) 2.00
Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor. Lancet (1988) 1.97
Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis (2008) 1.86
Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study. J Clin Endocrinol Metab (1998) 1.72
Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br J Gen Pract (1993) 1.57
Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol (Oxf) (1991) 1.57
Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med (2007) 1.56
Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol (Oxf) (1992) 1.56
Consensus statement: medical management of acromegaly. Eur J Endocrinol (2005) 1.54
Protein repletion and treatment in anorexia nervosa. Am J Clin Nutr (1994) 1.50
Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in the human kidney. J Am Soc Nephrol (1999) 1.47
An audit of management of differentiated thyroid cancer in specialist and non-specialist clinic settings. Clin Endocrinol (Oxf) (2001) 1.46
Thyroid hormone receptor expression in the "sick euthyroid" syndrome. Lancet (1990) 1.46
Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab (2001) 1.45
Clinical, quality of life, and economic value of acromegaly disease control. Pituitary (2011) 1.44
Mineralocorticoid hypertension and congenital deficiency of 11 beta-hydroxysteroid dehydrogenase in a family with the syndrome of 'apparent' mineralocorticoid excess. Clin Endocrinol (Oxf) (1995) 1.44
Diagnosis and treatment of thyroid nodules and goitre. J R Coll Physicians Lond (1998) 1.38
SI units: how systematic and how international are they? Ann Clin Biochem (1975) 1.38
Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement. BMJ (1996) 1.31
1alpha-Hydroxylase and the action of vitamin D. J Mol Endocrinol (2000) 1.30
Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase. Endocrinology (1999) 1.29
Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med (1998) 1.28
Giant invasive prolactinoma: a case report and review of nine further cases. Q J Med (1990) 1.28
Second-trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: experience of a regional programme. Prenat Diagn (1994) 1.26
Short term regulation of ureagenesis. J Biol Chem (1980) 1.26
Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab (2003) 1.24
Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology (2001) 1.24
Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) (1996) 1.23
Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab (1998) 1.23
Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab (2000) 1.22
Lack of association between serum TSH or free T4 and body mass index in euthyroid subjects. Clin Endocrinol (Oxf) (2006) 1.21
Reduced placental 11beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. J Clin Endocrinol Metab (2001) 1.21
Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab (2002) 1.18
Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab (2004) 1.18
11Beta-hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction. Hum Reprod (1998) 1.18
Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab (2002) 1.17
Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab (2002) 1.16
Thyroxine replacement treatment and osteoporosis. BMJ (1990) 1.14
Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism. QJM (1995) 1.14
Expression of type 2 11beta-hydroxysteroid dehydrogenase and corticosteroid hormone receptors in early human fetal life. J Clin Endocrinol Metab (1998) 1.13
The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology (2000) 1.11
Glucocorticoid activity, inactivity and the osteoblast. J Endocrinol (1999) 1.11
Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res (2001) 1.11
Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf) (2007) 1.09
Pituitary surgery for acromegaly. Should be done by specialists. BMJ (1999) 1.08
Failure of the normal ureagenic response to amino acids in organic acid-loaded rats. Proposed mechanism for the hyperammonemia of propionic and methylmalonic acidemia. J Clin Invest (1980) 1.07
11beta-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetologia (2008) 1.07
Weight gain following treatment of hyperthyroidism. Clin Endocrinol (Oxf) (2001) 1.07
A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol (2008) 1.06
Loss of estrogen inactivation in colonic cancer. J Clin Endocrinol Metab (1999) 1.06
11beta-Hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation. Mol Endocrinol (2004) 1.05
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab (2004) 1.05
Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon. QJM (1999) 1.05
Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxf) (2003) 1.03
Differential expression of oestrogen receptor and oestrogen inducible genes in gastric mucosa and cancer. Gut (1997) 1.02
Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. Endocrinology (1993) 1.02
The danger of using inappropriate point-of-care glucose meters in patients on icodextrin dialysis. Diabet Med (2011) 1.02
The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. J Clin Endocrinol Metab (1999) 1.01
ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab (2009) 1.01
Differential growth response to oestrogen of premalignant and malignant colonic cell lines. Anticancer Res (1994) 1.01
Expression profiling of 11beta-hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes. J Mol Endocrinol (2006) 1.01
Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet (1996) 1.01
CA-Repeat polymorphism in intron 1 of HSD11B2 : effects on gene expression and salt sensitivity. Hypertension (2000) 1.01
Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab (1999) 1.00
Fine needle aspiration cytology in diffuse or multinodular goitre compared with solitary thyroid nodules. BMJ (1993) 1.00
Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology (1989) 1.00
Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab (2001) 1.00
Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab (2006) 0.99
Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. Oncogene (2003) 0.99
Undescended testis and hormone levels in early pregnancy. J Epidemiol Community Health (1987) 0.99
Biphasic elevation of [Ca(2+)](i) in individual human spermatozoa exposed to progesterone. Dev Biol (2000) 0.98
Sex differences in the incidence of colorectal cancer: an exploration of oestrogen and progesterone receptors. Gut (1993) 0.98
Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. Heart (1996) 0.97
Biochemical abnormalities in anorexia nervosa and bulimia. Ann Clin Biochem (1987) 0.97
Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone. Bone (2000) 0.97
Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) (1998) 0.97